CCM
INSY

Cadence Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Cadence Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-175,040
Closed -$3.63M – 655
2014
Q1 		$3.63M Buy
175,040
+106,100
+154% +$2.1M 0.15% 266
2013
Q4 		$890K Buy
+68,940
New +$956K 0.03% 458

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
BTP
Bloom Tree Partners New York $215M AUM 17.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cadence Capital Management's INSY Position: Q2 2014 in Review

Cadence Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q2 2014, closing a stake of 175,040 shares — an estimated $3.63M sold.

Cadence Capital Management first reported a position in INSY in Q4 2013 and held it in 2 quarters. The position peaked at $3.63M in Q1 2014. 99 funds tracked by Wall St. Rank hold INSY as of Q2 2014.

  • Cadence Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • Cadence Capital Management sold 175,040 Insys Therapeutics, Inc. shares in Q2 2014, an estimated $3.63M.
  • Cadence Capital Management first reported a position in Insys Therapeutics, Inc. in Q4 2013 and held it in 2 quarters.
  • Cadence Capital Management's Insys Therapeutics, Inc. position peaked at $3.63M in Q1 2014.
  • 99 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2014.

Based on Cadence Capital Management's 13F filing for Q2 2014, filed 23 Jul 2014.